Peptides and their use for the treatment and / or prevention of multiple sclerosis
By using TSTA-3 and RASGRP2 peptides or polypeptides that are soluble in physiological solutions and coupled to cells, the problem of large side effects and insufficient effectiveness in existing MS treatments is solved. This achieves specific inhibition of pathogenic autoreactive cells in MS patients, blocking disease transmission, and is suitable for the treatment and prevention of early-stage MS patients.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- UNIVERSITY OF ZURICH
- Filing Date
- 2024-11-11
- Publication Date
- 2026-07-17
AI Technical Summary
Existing treatments for multiple sclerosis (MS) mainly rely on antigen-nonspecific immunomodulation or immunosuppression strategies, which have significant side effects and are not very effective, making it difficult to specifically suppress pathogenic autoreactive cells in the early stages of the disease.
Using peptides or polypeptides based on newly identified autoantigens TSTA-3 and RASGRP2, antigen-specific tolerance to MS is induced by coupling to cells such as erythrocytes or leukocytes in physiological solutions. The immunodominant fragments of these peptides are soluble and readily conjugated in physiological solutions, and treatment is carried out in combination with the T-cell specificity of specific patients.
It effectively induces antigen-specific tolerance in MS patients, reduces side effects, and can block autoreactive immune responses in the early stages of the disease, inhibiting disease transmission and spread. It is suitable for the treatment and prevention of early-stage MS patients.
Smart Images
Figure CN122422341A_ABST